The addition of pomalidomide to talquetamab in preclinical models of MM has also shown to enhance the anti-MM activity of talquetamab and showed a trend towards a lower T regulatory cell frequency with combination treatment ( 52 ).
← all excerpts
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
1
—
—